Trials / Unknown
UnknownNCT04604327
Comparison of Two Different Doses of Bemiparin in COVID-19
Ensayo clínico Aleatorizado, Abierto, Para Evaluar el Efecto de Dosis profilácticas o terapéuticas de Bemiparina en Pacientes Con COVID-19
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 164 (estimated)
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients requiring hospitalization due to COVID-19 pneumonia (non-severe) will be randomized to standard prophylactic doses or full therapeutic dose of bemiparin (a LMWH) for 10 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bemiparin sodium | Prophilactic vs full-dose for 10 days |
Timeline
- Start date
- 2020-10-26
- Primary completion
- 2021-05-31
- Completion
- 2021-07-31
- First posted
- 2020-10-27
- Last updated
- 2020-10-27
Locations
12 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT04604327. Inclusion in this directory is not an endorsement.